Auricular acupressure for cancer-related fatigue during lung cancer chemotherapy: a randomised trial

PurposeTo evaluate the effect of auricular acupressure (AA) on cancer-related fatigue (CRF), sleep disturbance and anxiety in lung cancer patients undergoing chemotherapy.Materials and methodsPatients were recruited from the respiratory department of a general hospital and were randomised into three groups. A 9-week course of AA using Semen Vaccariae (SV) (Group A)/AA using magnetic beads (Group B)/routine care (Group C) was implemented. CRF scores were used as the primary outcome while the sleep and anxiety scores were the secondary outcomes. Analysis of variance and least significant difference t-test were used to determine the intergroup differences and paired-sample t-test was used for the intragroup comparison.Results100 lung cancer patients undergoing chemotherapy were included. Compared with Group C, AA could significantly alleviate CRF (F:24.63, p<0.01), especially for physical and affective fatigue and Group A was more effective for managing physical fatigue than Group B in per-protocol (PP) (−1.75 (−2.69 to –0.82), p<0.01)/Intention to Treat analysis (ITT) (−1.41 (−2.39 to –0.41), p=0.01) analysis. However, AA had no effect on cognitive fatigue. Compared with Group C, only Group A produced significant improvements in sleep quality in PP analysis (−1.17 (−2.23 to –0.10), p=0.03) while it yielded negative results in ITT analysis (−0.82 (−1.74 to 0.10), p=0.08). Compared with Group C, AA could significantly reduce anxiety in PP analysis (F:9.35, p<0.01) while there was no statistical difference between Group B and Group C (−0.95 (−2.81 to 0.90), p=0.31), Group A and Group B (−1.26 (−3.12 to 0.59), p=0.18) in ITT analysis.ConclusionAA can alleviate CRF of lung cancer patients undergoing chemotherapy, especially for physical and affective fatigue. AA using SV is more effective for physical fatigue while AA using magnetic beads works better for anxiety. However, AA cannot improve the sleep quality.Trial registration numberISRCTNregistry (ISRCTN16408424).

Download Full-text

The Effects of Serum hs-CRP on the Incidence of Lung Cancer in Male Patients with Pulmonary Tuberculosis

Iranian Journal of Public Health ◽

10.18502/ijph.v48i7.2949 ◽

2020 ◽

Author(s):

Youhua JIANG ◽

Kewei NI ◽

Meiyu FANG ◽

Junling LIU

Keyword(s):

Lung Cancer ◽

Pulmonary Tuberculosis ◽

Cancer Patients ◽

Serum Levels ◽

Incidence Rates ◽

Lung Cancer Patients ◽

Group A ◽

Male Patients ◽

Hs Crp ◽

Group B

Background: This study intended to investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) on the incidence of lung cancer in male patients with pulmonary tuberculosis. Methods: A total of 1091 male patients with pulmonary tuberculosis in Zhejiang Cancer Hospital, Hangzhou, China from Jan 2009 to Jan 2012 were selected as the research objects. All patients were followed up from the beginning of hospitalization. According to serum hs-CRP level, patients were divided into two groups: group A (hs-CRP < 1 mg/L) and group B (hs-CRP > 3 mg/L). The relationship between baseline hs-CRP and the risk of lung cancer in patients with pulmonary tuberculosis was analyzed by multivariate Cox proportional risk regression model, and the serum levels of hs-CRP between lung cancer patients in all groups and other non-lung cancer patients were compared. Results: There were differences in age, drinking, smoking, diabetes history, body mass index (BMI), thyroglobulin (TG), history of hypertension and hyperglycemia among the three groups (P=0.036, 0.018, 0.040, 0.029, 0.006, 0.034, 0.020, 0.010). The serum levels of hs-CRP in patients with squamous carcinoma, adenocarcinoma and small cell carcinoma were significantly higher than those in non-lung cancer patients (P=0.022, 0.043, 0.011). The incidence rates of lung cancer in patients in group B and C were 1.37 and 1.69 times higher than that in group A, respectively. Conclusion: The increased serum level of hs-CRP will increase the incidence rate of lung cancer in male patients with pulmonary tuberculosis.

Download Full-text

Effect of Eye Movement Training on Sleep Quality of Patients with Advanced Lung Cancer Based on Pittsburgh Sleep Quality Index

Journal of Healthcare Engineering ◽

10.1155/2021/9811980 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Haiping Hu ◽

Wenying Yang ◽

Zhimin Liu ◽

Xiaona Zhang ◽

Junmei Shi ◽

...

Keyword(s):

Lung Cancer ◽

Sleep Quality ◽

Eye Movement ◽

Negative Emotion ◽

Advanced Lung Cancer ◽

Lung Cancer Patients ◽

Movement Training ◽

Pain Scores ◽

Group A ◽

Group B

Objective. To explore the effect of eye movement training on sleep quality of patients with advanced lung cancer based on the Pittsburgh Sleep Quality Index (PSQI). Methods. 120 advanced lung cancer patients admitted to our hospital from January 2019 to January 2020 were selected as the research object and divided into group A (PSQI scores ≥ 10 points, n = 60) and group B (PSQI < 10 points, n = 60). Routine nursing was performed to both groups, and patients in group A received the eye movement training additionally, so as to compare their PSQI scores, negative emotion scores, adverse reaction rate (ARR), Cancer Coping Modes Questionnaire (CCMQ) scores, and pain scores. Results. After training, group A obtained significantly better sleep quality ( P < 0.05 ), lower negative emotion scores ( P < 0.001 ), lower ARR ( P < 0.05 ), better CCMQ scores ( P < 0.05 ), and lower pain scores ( P < 0.001 ) than group B. Conclusion. Eye movement training should be promoted in practice because it can reduce negative emotions, alleviate pain sensation, improve sleep quality and body condition, and lower the ARR for advanced lung cancer patients.

Download Full-text

Dyspnea: Effect of Auricular Acupressure in End-Stage Lung Cancer Patients: A Pilot Feasibility Study (714)

Journal of Pain and Symptom Management ◽

10.1016/j.jpainsymman.2009.02.162 ◽

2009 ◽

Vol 37 (3) ◽

pp. 537

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Feasibility Study ◽

Lung Cancer Patients ◽

Auricular Acupressure ◽

End Stage ◽

Pilot Feasibility Study ◽

Stage Lung Cancer

Download Full-text

Self-reported sleep quality as prognostic for survival in lung cancer patients

Cancer Management and Research ◽

10.2147/cmar.s234523 ◽

2020 ◽

Vol Volume 12 ◽

pp. 313-321 ◽

Cited By ~ 1

Author(s):

Teodor Gottfried ◽

Iris Kamer ◽

Iris Salant ◽

Damien Urban ◽

Yaacov R Lawrence ◽

...

Keyword(s):

Lung Cancer ◽

Sleep Quality ◽

Cancer Patients ◽

Lung Cancer Patients

Download Full-text

Sleep Quality in Lung Cancer Patients

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2013.14.5.2909 ◽

2013 ◽

Vol 14 (5) ◽

pp. 2909-2913 ◽

Cited By ~ 5

Author(s):

Ruveyda Gelisken Akyuz ◽

Ozlem Ugur ◽

Ayfer Elcigil

Keyword(s):

Lung Cancer ◽

Sleep Quality ◽

Cancer Patients ◽

Lung Cancer Patients

Download Full-text

Prof. Zhenye Xu’s Experience on Treating Cancer-Related Fatigue of Advanced Lung Cancer Patients

Traditional Chinese Medicine ◽

10.12677/tcm.2015.42003 ◽

2015 ◽

Vol 04 (02) ◽

pp. 13-17

Author(s):

明玉阮

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Advanced Lung Cancer ◽

Lung Cancer Patients ◽

Cancer Related Fatigue

Download Full-text

Comparative effectiveness assessment of a lung cancer multidisciplinary practice to improve patient care.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e16523 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e16523-e16523

Author(s):

Hamid R. Mirshahidi ◽

Elvin Hernandez ◽

Matthew Ta ◽

Sheley M Baylon ◽

Minh Thy Pham ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Early Stage ◽

Stage Iv ◽

Stage I ◽

Tumor Board ◽

Survival Difference ◽

Group A ◽

One Year ◽

Group B

e16523 Background: Multidisciplinary focused-care teams have shown beneficial outcomes in diagnosis and treatment in cancer patients as well as assist in providing accessible, cohesive and continuous care. The multidisciplinary team specializing in thoracic cancer at our institution includes thoracic surgeons, pulmonologists, medical oncologists, radiation oncologists, pathologists, radiologists and a weekly tumor board with the inclusion of a dietician, a pharmacist, and a psych/social worker. This study examined the effectiveness of a multidisciplinary focused program in improving overall care in lung cancer patients. Methods: Lung cancer patient data between January 2000-December 2009 were abstracted from the institutional cancer registry. Patient demographics, treatment received, and survival (1-year and 2-year) were compared between Group A (January 2000-July 2005) and Group B (August 2005-December 2009) using Fisher’s exact test. Results: 1202 patients (Group A = 760; Group B = 442) were evaluated. Majority of patients were > 60 years old, male, and has stage IV adenocarcinoma. Missing stage was less in Group B (13.8% vs 17.4%). Early stage patients in Group B received more surgeries and less inappropriate treatments. More palliative chemotherapy/radiation treatments were given in Group B late stage disease. More stage II (21.1% vs 2.3%) and IIIA (12% vs 1.5%) patients in Group B were treated with wedge resection and chemotherapy. One-year survival differences were seen between 2 groups in stage I, IIIA, and IV (P <0.05). 2-year survival difference was seen in stage IV disease (P<0.05). Conclusions: Introduction of multidisciplinary lung care team between 2005-2009 was associated with an increased patients being staged and more appropriate treatments. One year survival almost doubled in stage I patients where stage IV pts experienced up to 4 times improvement in 1- and 2-year survival. The results of the present evaluation appear to confirm the value of a multidisciplinary approach to the management of patients with lung cancer.

Download Full-text

Observation of clinical efficacy and survival of lung cancer patients with UMIPIC combined with low-dose chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e21605 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e21605-e21605

Author(s):

Jianbin Feng ◽

Peng Jing ◽

Feng Gao ◽

Jian Liu ◽

Wei Han ◽

...

Keyword(s):

Lung Cancer ◽

Survival Time ◽

Clinical Efficacy ◽

Adverse Reactions ◽

Low Dose ◽

Survival Rates ◽

Lung Cancer Patients ◽

Group A ◽

Group B ◽

Low Dose Chemotherapy

e21605 Background: To observe the clinical efficacy and survival of UMIPIC combined with low-dose chemotherapy in patients with lung cancer. Methods: 840 patients with lung cancer underwent UMIPIC treatment from January 2011 to December 2015 were selected as the study subjects, 341 cases combined with low-dose chemotherapy in group A and 499 cases not combined with chemotherapy in group B. All patients were diagnosed with lung cancer and signed a consent form for treatment. The patients were treated according to the UMIPIC treatment guidelines. This study was mainly to observe the adverse reactions, clinical efficacy, survival time and survival rate of lung cancer patients after receiving UMIPIC combined with or without low dose chemotherapy. Results: The common adverse reactions in group A were fever 38.12%, followed by pain 9.38%, hemoglobin 7.94%, white blood cells 5.01%, nausea 2.35%, liver function damage 1.19%, vomiting 1.17%, and kidney function damage 0.30%; Common adverse reactions in group B were fever 38.68%, followed by pain 13.23%, hemoglobin reduction 12.87%, white blood cell reduction 5.29%, nausea 2.00%, vomiting 2.00%, liver function damage 1.92%. The hemoglobin reduction in group A was significantly lower than that in group B (P < 0.05), and there was no difference in the other adverse reactions (P > 0.05). Clinical efficacy of the two groups revealed that the benefit rate of group A was 95.45% higher than that of group B 93.47% (P > 0.05). After follow-up, it was found that the average survival time and median survival time of patients in group A were 20.744 and 13.270 months, respectively, which were significantly higher than those of group B at 19.514 and 10.070 months (P < 0.05). The survival rates of the two groups of patients, The 1-year, 2-year, and 5-year survival rates of group A patients are 52.48%, 23.60%, and 16.95%, and the 1-year, 2-year, and 5-year survival rates of group B patients are 42.96% and 17.07 % And 10.26%, the one-year survival rate of group A was significantly higher than that of group B (P < 0.05). Conclusions: UMIPIC combined with low-dose chemotherapy has a good clinical effect in treating lung cancer without increasing the incidence of adverse reactions, and a significant effect on extending survival time and improving survival rate of lung cancer patients.

Download Full-text